Thetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patients
Phase 1a Results Highlight TP-317’s Safety, Tolerability, and Target Engagement Phase 1b Trial Planned for 2025 January 09, 2025 07:00 AM Eastern Standard Time ESSEX, Conn.–(BUSINESS WIRE)–Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317,…